Table 1.
Baseline characteristics by baseline renal function
| Baseline characteristics | All Patients (N = 1789) | eGFR ≤45 (N = 73) | eGFR >45 (N = 1716) | P-value |
|---|---|---|---|---|
| Female, n(%) | 649 (36) | 40 (55) | 609 (36) | <0.001 |
| Age ≥65 years,n (%) Race, n (%) |
288(16) | 17 (24) | 271 (16) | 0.09 |
| White | 1428(80) | 52(71) | 1376 (80) | 0.06 |
| Black or African American | 218(12) | 16 (22) | 202 (12) | 0.01 |
| Asian / Pacific Islander | 45 (3) | 1 (1) | 44 (3) | 0.54 |
| Other | 86(5) | 3 (4) | 83 (5) | 0.79 |
| Missing | 12(1) | 1 (1) | 11 (1) | 0.46 |
| Hispanic ethnicity, n (%) HCV genotype, n (%) |
123(7) | 7(10) | 116 (7) | 0.36 |
| 1a | 806 (45) | 33 (45) | 773 (45) | 0.98 |
| 1b | 353 (20) | 15(21) | 339 (20) | 0.90 |
| 1 w/subtype not specified | 126(7) | 8(11) | 117 (7) | 0.10 |
| 2 | 295(17) | 11 (15) | 284 (17) | 0.73 |
| 3 | 161 (9) | 4(6) | 157 (9) | 0.28 |
| 4 | 36(2) | 1 (1) | 35 (2) | 0.71 |
| 5, 6 or other | 12(1) | 1 (1) | 11 (1) | 0.84 |
| Q80K polymorphism, n/N (%) | 53/114 (47) | 2/6 (33) | 51/108 (47) | 0.68 |
| Prior HCV treatment experience, no (%) | 950 (53) | 39(53) | 911 (53) | 0.96 |
| Prior 1st generation PI triple therapy experience, n (%) | 176(10) | 6 (8) | 170 (10) | 0.64 |
| Cirrhosis, n (%) | 930(52) | 47 (64) | 883 (52) | 0.03 |
| History of decompensation, n (%) | 437 (24) | 34(73) | 403 (24) | <0.001 |
| MELD ≥10, n (%) | 699(39) | 73(100) | 626 (36) | <0.001 |
| HIV, n (%) | 39(2) | 3 (4) | 36 (2) | 0.25 |
| Liver transplant, n (%) | 211 (12) | 36 (49) | 175 (10) | <0.001 |
| Kidney transplant*, n (%) Immunosuppression, n (%) | 22(1) | 6 (8) | 16 (1) | <0.001 |
| Tacrolimus | 181 (10) | 32 (44) | 149 (9) | <0.001 |
| Cyclosporine | 29(2) | 3 (4) | 26 (1) | 0.09 |
| Everolimus/sirolimus | 31 (2) | 7(10) | 24 (1) | <0.001 |
| Mycophenolate mofetil/mycophenolic acid | 109(6) | 23 (32) | 86 (5) | <0.001 |
| Hepatocellular carcinoma, n (%) | 186(10) | 15(21) | 171 (10) | 0.004 |
| Diabetes, n (%) | 415(23) | 32 (44) | 383 (22) | <0.001 |
| Haemodialysis, n (%) | 5 (<0.5) | 5 (7) | 0 (0) | <0.001 |
| Erythropoietin stimulating agent use at baseline, n (%) | 64 (4) | 6 (8) | 58 (3) | 0.03 |
| Total bilirubin (mg/dl), median (IQR) | 0.8 (0.5–1.2) | 0.7 (0.5–1.3) | 0.8 (0.5–1.2) | 0.44 |
| ALT (IU/L), median (IQR) | 65(41–110) | 50(31–79) | 66 (43–112) | <0.001 |
| Albumin (g/dl), median (IQR) | 4.0 (3.5–4.3) | 3.8 (3.3–4.2) | 4.0 (3.5 –4.3) | 0.02 |
| Haemoglobin (g/dl), median (IQR) | 14.2(13.1–15.3) | 12.1 (10.7–13.9) | 14.3 (13.2–15.4) | <0.001 |
| Platelets (× 103/μl), median (IQR) | 148 (95–208) | 138 (89–200) | 149 (96–208) | 0.21 |
| INR, median (IQR) | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 0.60 |
| HCV RNA (106 IU/ml), median (IQR) | 1.6 (0.5–4.3) | 1.9 (0.5–3.8) | 1.6 (0.5 –4.3) | 0.61 |
*
Eighteen patients with both liver and kidney transplants: 3 eGFR ≤45 ml/min/1.73 m2, 15 eGFR >45 ml/min/1.73 m2.
ALT, alanine aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; INR, international normalized ratio; MELD, model for end-stage liver disease; PI, protease inhibitor.